DEA Regulations for Telehealth Ketamine
The Drug Enforcement Administration's regulations form the federal backbone of legal telehealth ketamine prescribing. Understanding these rules—which ones currently apply, which ones are proposed, and how they interact with state law—is important for both patients and providers.
Ketamine's Schedule III Classification
Ketamine is classified as a Schedule III controlled substance under the Controlled Substances Act. This classification positions ketamine as:
- Having accepted medical uses (as an anesthetic and, off-label, as a psychiatric treatment)
- Having moderate to low physical dependence potential
- Having moderate psychological dependence potential
- Being subject to prescription and dispensing requirements less strict than Schedule I or II drugs but more strictly regulated than Schedule IV or V
Schedule III Prescription Requirements
Ketamine prescriptions must comply with Schedule III regulations:
- Prescriptions may be written, oral (telephoned to a pharmacy), or electronic
- Oral prescriptions must be reduced to writing by the pharmacy
- Prescriptions may be refilled up to 5 times within 6 months of the original issue date
- After 6 months or 5 refills, a new prescription is required
- Prescriptions must include: patient name and address, date of issuance, drug name and strength, quantity, directions for use, number of refills authorized, prescriber name and address, DEA number
Electronic prescribing of controlled substances (EPCS) is now widely used and legally permissible for Schedule III substances.
The Ryan Haight Act: The Original Barrier
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 was named for a California teenager who died after obtaining controlled substances through an online pharmacy without a legitimate prescription. The Act's primary provision for our purposes: a practitioner cannot prescribe a controlled substance to a patient via the internet without first conducting an in-person medical evaluation.
The Ryan Haight Act defined "practice of telemedicine" narrowly. It allowed telemedicine prescribing only in specific circumstances:
- The patient is located at a DEA-registered hospital or clinic
- The patient is located at a DEA-registered hospital or clinic and there is a DEA-registered practitioner present during the telemedicine evaluation
Neither exception covered a patient at home connecting to a provider via video—the model that defines consumer telehealth. The Ryan Haight Act effectively barred the direct-to-consumer telehealth ketamine model until the COVID exemptions changed the landscape. Our Ryan Haight Act guide covers this history in depth.
COVID-19 Emergency Exemptions
On March 16, 2020, the DEA issued a temporary order expanding access to telemedicine prescribing of controlled substances. Key provisions:
- DEA-registered practitioners could prescribe controlled substances via telemedicine without a prior in-person evaluation
- This applied to all Schedule II-V controlled substances, including ketamine (Schedule III)
- The prescription must be issued for a legitimate medical purpose in the usual course of professional practice
- The practitioner must have an established patient-practitioner relationship (established via the telemedicine encounter itself)
- The practitioner must comply with applicable federal and state laws
- Prescriptions must note they were issued pursuant to the public health emergency
This exemption created the legal foundation for the telehealth ketamine industry's growth from 2020 onward.
Extensions and Current Status
The COVID public health emergency formally ended in May 2023. The DEA did not immediately reinstate Ryan Haight's in-person requirement. Instead, the DEA issued a series of temporary rules extending the COVID telemedicine flexibilities while working on permanent regulations. As of early 2025, these extensions remain in effect.
The extensions were renewed partly because the DEA's proposed permanent rules generated substantial public opposition (over 38,000 public comments), requiring revision and additional development time.
The Proposed Special Registration Framework
The SUPPORT for Patients and Communities Act of 2018 directed the DEA to create a "special registration" for practitioners who prescribe controlled substances via telemedicine without a prior in-person visit. The DEA has been developing this framework since 2018.
In 2023, the DEA published proposed rules for two categories of telemedicine prescribing:
Proposed Category 1: Telemedicine Prescribing for Non-Narcotic Schedule III-V
This category would allow practitioners registered with the DEA and meeting certain criteria to prescribe non-narcotic Schedule III-V controlled substances (including ketamine) via telemedicine without a prior in-person visit. Requirements under the proposal included:
- Practitioner must hold a DEA registration
- Prescription limited to a 30-day supply
- The practitioner must check the state PDMP before prescribing
- The patient must provide valid government-issued ID
- An in-person evaluation is required before a second prescription can be issued
The 30-day limit and in-person requirement for continuation prescriptions were heavily criticized by telehealth providers as operationally problematic.
Proposed Category 2: Telemedicine Prescribing with Special Registration
This category would allow practitioners who obtain a special DEA telemedicine registration to prescribe Schedule II-V controlled substances via telemedicine indefinitely, with ongoing requirements including PDMP checks, identity verification, and record-keeping.
The proposed rules were withdrawn for revision after the public comment period. As of early 2025, finalized permanent rules are still pending.
Record-Keeping Requirements
DEA regulations require practitioners to maintain records of all controlled substance prescriptions for at least two years. For telehealth prescribing, these records should include documentation of the telemedicine encounter, the clinical rationale for prescribing, and any PDMP check conducted.
Prescription Monitoring Program (PDMP) Requirements
PDMPs are state-operated databases that track controlled substance prescriptions. Most states require prescribers to check the PDMP before issuing a controlled substance prescription, and most require dispensers to report prescriptions to the PDMP.
For telehealth ketamine prescribers operating across multiple states, PDMP compliance requires understanding each state's specific requirements—some states require PDMP checks for all Schedule II-V prescriptions; others focus on Schedule II-III; some have frequency requirements (every 90 days, every visit, etc.).
Practical Compliance for Telehealth Providers
A compliant telehealth ketamine provider:
- Holds a valid DEA registration
- Conducts clinical video evaluations before prescribing
- Checks the patient's state PDMP before each prescription
- Prescribes only for legitimate medical purposes with documented clinical rationale
- Maintains records for the required retention period
- Stays current on DEA emergency extension status and adjusts practices as permanent rules are finalized (see our state regulations overview for how federal and state rules interact)
References
- StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
- PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
- MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
- HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
- SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service
Share